NEW YORK, May 16 - Variagenics said today it plans to lay off 30 percent of its workforce and jettison its NuCleave business in an attempt to reign in cash burn and focus more tightly on its molecular diagnostics business.
Registering provides access to this and other free content.
Already have an account?Login Now.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.